Robert Temple
United States Food and Drug Administration · 118 works · 8,838 citations · h-index 40
Top works
- Real-World Evidence — What Is It and What Can It Tell Us?
- Food and Drug Administration requirements for approval of new anticancer drugs.
- The FDA's assessment of follow-on protein products: a historical perspective
- The FDA's Critique of the Anturane Reinfarction Trial
- Design and analysis of non‐inferiority mortality trials in oncology
- Government Viewpoint of Clinical Trials
- Are Surrogate Markers Adequate to Assess Cardiovascular Disease Drugs?
- Women in Clinical Trials of New Drugs -- A Change in Food and Drug Administration Policy
- Antithrombotic drug development for atrial fibrillation: Proceedings, Washington, DC, July 25-27, 2005
- Hy's law: predicting serious hepatotoxicity
- Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration
- The Prevention and Treatment of Missing Data in Clinical Trials: An FDA Perspective on the Importance of Dealing With It
- Meta-analysis and Epidemiologic Studies in Drug Development and Postmarketing Surveillance
- New Era in Drug Interaction Evaluation: US Food and Drug Administration Update on CYP Enzymes, Transporters, and the Guidance Process
- Problems in interpreting active control equivalence trials
- Stimulation of Steroid Secretion in Adrenal Tumor Cells by Choleragen
- The Use of Lithium in the Treatment of Thyrotoxicosis
- Is This the Drug or Dose for You?: Impact and Consideration of Ethnic Factors in Global Drug Development, Regulatory Review, and Clinical Practice
- Erythropoiesis-Stimulating Agents — Time for a Reevaluation
- Stimulation of Steroid Secretion by Antimicrotubular Agents